

Chromolaena odorata: A neglected weed with a wide spectrum of pharmacological activities (Review)

KAVITHA VIJAYARAGHAVAN^{1*}, JOHANNA RAJKUMAR², SYED NASIR ABBAS BUKHARI³,
BADR AL-SAYED⁴ and MOHAMMED ALI SEYED^{3,4*}

¹School of Life Sciences, B.S. Abdur Rahman University, Chennai, Tamil Nadu 600048; ²Department of Biotechnology, Rajalakshmi Engineering College, Chennai, Tamil Nadu 602105, India; ³Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur 50300, Malaysia; ⁴Faculty of Medicine, University of Tabuk, Tabuk 71491, Saudi Arabia

Received December 25, 2015; Accepted September 23, 2016

DOI: 10.3892/mmr.2017.6133

Abstract. The study of wound-healing plants has acquired an interdisciplinary nature with a systematic investigational approach. Several biochemicals are involved in the healing process of the body, including antioxidants and cytokines. Although several pharmaceutical preparations and formulations are available for wound care and management, it remains necessary to search for efficacious treatments, as certain current formulations cause adverse effects or lack efficacy. Phytochemicals or biomarkers from numerous plants suggest they have positive effects on different stages of the wound healing process via various mechanisms. Several herbal medicines have displayed marked activity in the management of wounds and various natural compounds have verified *in vivo* wound healing potential, and can, therefore, be considered as potential drugs of natural origin. *Chromolaena odorata* (L.) R.M. King and H. Robinson is considered a tropical weed. However, it exhibits anti-inflammatory, antipyretic, analgesic, antimicrobial, cytotoxic and numerous other relevant medicinal properties on an appreciable scale, and is known in some parts of the world as a traditional medicine used to treat various ailments. To understand its specific role as nature's gift for healing wounds and its contribution to affordable healthcare, this plant must be scientifically assessed based on the available literature. This review aims to summarize the role of *C. odorata* and its biomarkers in the wound healing activities of biological systems, which are crucial to its potential future

drug design, development and application for the treatment of wounds.

Contents

1. Introduction
2. Plant-derived wound healing agents
3. *Chromolaena odorata* as nature's wound healer
4. Chemical constituents of *Chromolaena odorata*
5. Pharmacological activities and wound healing mechanism
6. Conclusion

1. Introduction

Wounds are physical injuries that can be classified as 'open' or 'closed', based on the underlying cause, and 'acute' or 'chronic', based on the physiology of wound healing (1-3). Wound healing is essential for the restoration of disrupted anatomical integrity and disturbed function of the affected area (4,5). Healing is a complex and intricate process, initiated in response to an injury, that serves to restore the function and integrity of the damaged tissues (6). Chronic wounds are a major concern for patients and clinicians, affecting a large number of patients and leading to a serious reduction in their quality of life (7). Recent estimates indicate that ~6 million people suffer from chronic wounds worldwide (7,8), while in the US, traumatic wounds result in >300,000 hospitalizations annually (7,8).

The restoration of the affected area is the main aim of quality wound rehabilitation. Surgical wounds account for the vast majority of skin injuries, with ~80% of these wounds requiring the use of some form of closure product, such as sutures, staples or tape, while numerous wound management strategies use hemostasis products, fabric bandages and surgical dressings (9,10).

Wound healing is a normal biological process in the human body that is achieved via four rigidly coordinated phases: Hemostasis, inflammation, proliferation and remodeling (4,6). Wound healing, therefore, involves a number of processes, including inflammation, cell proliferation and contraction of the collagen lattice (11-13). In addition, the healing process

Correspondence to: Professor Mohamed Ali Seyed, Faculty of Medicine, University of Tabuk, Duba Road, Tabuk 71491, Saudi Arabia
E-mail: sdmdali.ali@gmail.com

*Contributed equally

Abbreviations: ECM, extracellular matrix; HO-1, heme oxygenase-1; MMP, matrix metalloproteinase; PMNL, polymorphonuclear leukocytes; ROS, reactive oxygen species

Key words: *Chromolaena odorata*, wound healing, weed, signaling

may be hampered by the presence of oxygen free radicals or microbial infection (5,6). Over the last 15 years, the *in vitro* tests developed to investigate wound healing have exploited all of these processes as targets for enhancing its management. Since the different phases of the wound healing process overlap, an ideal plant-based remedy should affect at least two phases before it can be considered to have scientific support for its use (12-14). Despite significant advances in the pharmaceutical industry, the pursuit of effective and low cost therapies for wound healing remains a challenge for modern medicine due to the potentially chronic nature of injuries and the side effects associated with current therapies (15-19). In the search for novel therapeutic options, plants and their metabolites represent an important potential source of biomolecules.

2. Plant-derived wound healing agents

Numerous medicinal plants have been reported to possess wound healing activity (20-28). During the 20th century, 80% of the world population depended on traditional medicine for their primary healthcare requirements (29). Medicinal plants continue to serve an important role in healthcare as a source of novel drugs, and herbal and food supplements. However, several ethnic groups have failed to retain their historical collective knowledge of such medicinal plant use (30); the disappearance of traditional cultural and natural resources due to population growth, urbanization, and the erosion of botanical knowledge in developing countries may result in the potentially permanent loss of such unrecorded knowledge and information (31). Folk and tribal medicine practices employ numerous plants and animal products for the treatment of cuts, wounds and burns (12). Some of these plants have been screened scientifically to evaluate their wound healing activity in different pharmacological models and human subjects; however, the potential of most of these plants remains unexplored (29-31). It is, therefore, critical to ensure that the agents that are currently used in traditional systems of medicine do not disappear from use before they can be fully assessed and documented (32).

Research on wound healing agents is one of the emerging areas in modern biomedical sciences (33-37). For medicinal plants to properly contribute to affordable healthcare, they must be scientifically assessed; phytochemical screenings are often considered as the first step towards the discovery of useful drugs (38,39). Successive solvent extraction techniques, as well as chromatographic separations and spectroscopic methods, have been used to determine the chemical constituents of plants and study their bioactivity as it applies to traditional medicine (32,37). A number of secondary metabolites and active compounds isolated from plants have been demonstrated as active facilitators of wound healing in animal models. Important examples include: Tannins from *Terminalia arjuna* (40); oleanolic acid from *Anredera diffusa* (41); polysaccharides from *Opuntia ficus-indica* (42); gentiopicoside, sweroside and swertiamarin from *Gentiana lutea* (43); shikonin derivatives (deoxyshikonin, acetyl shikonin, 3-hydroxy-isovaleryl shikonin and 5,8-odimethyl acetyl shikonin) from *Onosma argentatum* (44); asiaticoside, asiatic acid and madecassic acid from *Centella asiatica* (45-47); quercetin, isorhamnetin and kaempferol from *Hippophae rhamnoides* (48);

curcumin from *Curcuma longa* (49); oleoresin from *Copaifera langsdorffii* (50); proanthocyanidins and resveratrol from grapes (51,52), acylated iridoid glycosides from *Scrophularia nodosa* (53); phenolic acids (protocatechuic, p-hydroxybenzoic, p-coumaric, ferulic and vanillic acids) from *C. odorata* (54,55); glycoprotein fraction of *Aloe vera* (56); (+)-epi-alpha-bisabolol from *Peperomia galioides* (57); fukinolic and cimicifugic acids from *Cimicifuga* spp. (58); and xyloglucan from *Tamarindus indicus* (59).

A major challenge to the pharmacological validation of wound healing plants, is that the exact mechanism of the process of wound healing is not clearly understood; wound healing is known to be a complicated process involving a number of stages, including inflammation, epithelization, antioxidant defense and biochemical changes (hydroxyproline), granulation, neovascularization and wound contraction (60), however, the precise mechanistic details remain unclear. The majority of research studies into medicinal plants are, therefore, restricted to screening plants to simply evaluate their wound healing effects and investigate the mechanistic details. This review aims to evaluate the current knowledge and information available regarding the underutilized and neglected medicinal plant *C. odorata*, including its mechanism of action *in vitro* and *in vivo*, and to examine the ethnopharmacological claims of the usefulness of this plant. This may contribute to encouraging the global acceptance of wound healing agents of plant origin and the recognition of their important natural role in wound healing. To support this, a study reported that ~31% of these medicinal plants have been used to treat wounds, 29% have been used to treat cuts, 10% to treat burns, and 22% to treat cuts and wounds (27,61).

3. *Chromolaena odorata* as nature's wound healer

C. odorata [Linn (L.)] King and Robinson (formerly known as *Eupatorium odoratum* L. Table I), belongs to the kingdom Plantae, subkingdom Tracheobionta (vascular plants), superdivision Spermatophyta (seed plants), division Magnoliophyta (flowering plants), class Magnoliopsida (dicotyledons), subclass Asteridae, order Asterales, family Compositae, genus *Chromolaena* DC (Thoroughwort), and species *C. odorata* (L.) (62-67). It belongs to the largest family of flowering plants, which contains about 900 genera and 13,000 species (62-67). *C. odorata* is also known as *Eupatorium conyzoides* Vahl, *Eupatorium brachiatum* Siam weed. ex Wiestr, *Eupatorium atriplicifolium* Vahl and *Osmia odorata* (L.) Schultz-Bip. It is colloquially known in English by names including Siam weed, trifid weed, bitter bush, Jack in the Bush, Christmas bush and baby tea, and by numerous other names in other countries and languages (68).

The genus *Chromolaena* includes 1,200 species of small herbs, shrubs or subshrubs distributed chiefly in the Americas, a few in Europe, Asia, and tropical Africa (54,55,67,69,70). *C. odorata*, and closely related *Eupatorium* spp., have been discovered in Europe including France, Thailand, China and Indo-China (54,55,66,69,71). Compared with other large families, such as Leguminosae, the number of important economic products derived from the family Compositae is relatively small (62,65). *C. odorata* is a diffuse and scrambling perennial shrub that grows to a height of 3-7 m in the open (72-75).

Table I. General information about *C. odorata*.

Scientific name	<i>Chromolaena odorata</i>
Taxonomic name	<i>Chromolaena odorata</i> (Linn) King & Robinson
Family	Asteraceae (Compositae)
Genus	<i>Chromolaena</i>
Synonym	<i>Eupatorium odoratum</i>
Organism type	Herb (54,64)
Habitat	Agricultural areas, natural forests, planted forests, range/grasslands, riparian zones, ruderal/disturbed, scrub/shrublands (74).
Common names	Siam weeds (64,65,66,67,69,80); Triffed weeds (64,65); Bitter bush/Jack in the bush (64,65); Pokok kapal terbang or aeroplane plant (69,80); Pokok Jerman (69)

It is a prolific weed that thrives in the majority of soil types, is found in abundance on open wasteland and along roadsides, and prevents the establishment of other flora (76,77). *C. odorata* is a poisonous plant that contains exceptionally high levels of nitrates in young plants, at 5-6 times greater than the level toxic to wildlife (78). It is considered a menace because it affects plantations and other ecosystems due to its invasive nature (66,79).

As outlined in Fig. 1, *C. odorata* has been reported to exhibit antibacterial, antiplasmodic, antiprotozoal, antitrypanosomal, antifungal, antihypertensive, anti-inflammatory, astringent, diuretic, hepatotropic (54,55,66,80-82), immunomodulatory (83) and anticancer effects (84-90). It is also applied topically as an antidote to the sting of the spine of the common sea catfish (86). Traditionally, fresh leaves or a decoction of *C. odorata* have been used throughout Vietnam and other tropical countries for the treatment of leech bites, soft tissue wounds, burn wounds, skin infections, rashes, diabetes and periodontitis, and as an insect repellent (54,55,91-93). A poultice of the leaves is traditionally applied to cuts or wounds to stop bleeding and promote healing (69,76,93). Eupolin, a product made from *Chromolaena* spp., has already been licensed for use in Vietnam for the treatment of soft tissue burns and wounds (69,94-97). An aqueous decoction of the roots is used as an antipyretic and analgesic remedy, and a leaf extract with salt is used as a gargle for sore throats and colds (69). The fresh leaves and extracts of *C. odorata* are traditional herbal treatments in certain developing countries, including Thailand, India and Vietnam, for burns, soft tissue wounds, and skin infections (81,94,96).

4. Chemical constituents of *Chromolaena odorata*

Several chemical analyses of *C. odorata* L. have been undertaken that have identified constituents including monoterpenes, sesquiterpenes hydrocarbons, triterpenes/steroids, alkaloids and flavonoids (98-100). The leaves of this plant have been found to be a rich source of flavonoids including

quercetin, sinensetin, sakuranetin, padmatin, kaempferol and salvagenin (86,98). The leaves of *C. odorata* also contain the highest concentration of allelochemicals isolated from a plant (98). A study in Vietnam revealed that the aqueous extract of the leaf contained flavonoids (salvigenin, sakuranetin, isosakuranetin, kaempferide, betulenol, 2-5-7-3 tetra-o-methyl quercetagenin, tamarixetin, two chalcones and odoratin and its alcoholic compound), essential oils (geyren, bornyl acetate and β -eubeden), saponin triterpenoids, tannins, organic acids and numerous trace substances (99). Another study by Heiss *et al* (100) demonstrated that the crude ethanol extract of *C. odorata* contains phenolic acids (protocatechuic, p-hydroxybenzoic, p-coumaric, ferulic and vanillic acids) and complex mixtures of lipophilic flavonoid aglycones (flavanones, flavonols, flavones and chalcones). To date, studies on *C. odorata* have resulted in the isolation of 17 compounds, including 5 α , 6,9,9 α ,10-pentahydro-10 β -hydroxy-7-methylanthra[1,2-d][1,3]dioxol-5-one, 1,2-methylenedioxy-6-methylanthraquinone, 3-hydroxy-1,2,4-trimethoxy-6-methylanthraquinone, 3-hydroxy-1,2-dimethoxy-6-methylanthraquinone and 7-methoxy-7-epi-medioresinol, as well as 12 known compounds including odoratin, 3 β -acetyloleanolic acid, ursolic acid, ombuin, 4,2'-dihydroxy-4',5',6'-trimethoxychalcone, (-)-pinosresinol, austrocortinin, tianshic acid, cleomiscosin D, (-)-medioresinol, (-)-syringaresinol, and cleomiscosin A (99). Fig. 2 presents the chemical structures of a few of the important bioactive compounds in *C. odorata*, including stigmaterol, scutellarein tetramethyl ether (Scu; 4',5,6,7-tetramethoxy-flavone), flavonoids (98,99,101,102), and the phytylpropane compound chromomoric acid C-1 (100).

5. Pharmacological activities and wound healing mechanism

Wound healing is an intricate process by which the skin or other organs and tissues self-repair following injury (103). In normal skin, the epidermis and dermis form a protective barrier against the external environment. The moment the injury occurs and this protective barrier breaks, the process of wound healing is immediately activated, and can continue for months or years (3). Wound healing involves continuous cell-cell and cell-matrix interactions (104), and requires the collaborative efforts of numerous different tissues and cell types, including platelet aggregation and blood clotting, fibrin formation, inflammation, angiogenesis and reepithelialization (105,106). Healing is considered complete once the disrupted surfaces are firmly knitted together by collagen (107). Optimal wound healing involves minimizing tissue damage and providing adequate tissue perfusion and oxygenation, proper nutrition and a moist wound healing environment to restore function to the injury site (108).

The most established effect of *C. odorata* is on wound healing. The constituents of the plant extracts modulate one or more of the overlapping wound healing stages. Extracts of the leaves and other plant parts of *C. odorata* (Table II) have been demonstrated to be beneficial in the treatment of wounds and other disorders (54,55,69,71-73,92,109-112). For its traditional usage in wound healing, a paste of ground leaves is applied topically to the affected area (97,113). *In vitro* and *in vivo* studies of these extracts have demonstrated that they enhanced fibroblast,




Figure 1. Cellular and bio-physiologic events associated with treatment with *Chromolaena odorata* extract.

endothelial cell and keratinocyte proliferation; stimulated keratinocyte migration *in vitro* (54,55); upregulated the keratinocyte-induced production of extracellular matrix (ECM) proteins and basement membrane components; and inhibited collagen lattice contraction by fibroblasts (85,90,94,95).

The process of wound healing involves four overlapping phases: Hemostasis (cessation of bleeding), inflammation, proliferation and remodeling (114-116). Thromboxane synthase is the primary regulator of hemostasis; the enzyme that converts prostaglandin H_2 to thromboxane A_2 , which has potent vasoconstriction and platelet aggregation activity (117). Plasminogen activator inhibitor type 1 is also involved in hemostasis by inhibiting fibrinolysis, which prevents failure of the hemostasis (118). Subsequently, during the inflammatory phase, free radicals are released from neutrophils to kill bacteria (119,120), and heme and heme proteins locally accumulate at the wound site. Heme and heme proteins exert prooxidative and proinflammatory effects via increasing the expression level of adhesion molecules, increasing vascular permeability and increasing leukocyte infiltration, which induce wound healing. Heme oxygenase-1 (HO-1) is anti-inflammatory and is an antioxidant involved in a variety of wound healing processes. HO-1 produces biliverdin/bilirubin, iron, and carbon monoxide from heme, which have

potent antioxidant effects. HO-1 overexpression accelerates wound healing by reducing inflammation, increasing proliferation, and inhibiting endothelial cell apoptosis (121). Matrix metalloproteinases (MMPs) are also important in wound healing via effects on remodeling of the ECM (122). MMP-9 is key effector among MMP proteins (123). Various reports have demonstrated that *C. odorata* extract accelerates hemostasis (124-126) and wound healing (54,94,95). In addition, Scu and stigmaterol also exhibit hemostatic (127) and anti-inflammatory activities (101,102,128). The phytoprostane compound chromomoric acid C-I has been identified in *C. odorata* as a strong inducer of nuclear factor, erythroid 2 like 2 (Nrf2) activity, which is a major regulator of various genes, including NADPH:quinone reductase, glutathione S-transferase, γ -glutamylcysteine synthetase, UDP-glucuronosyltransferases and epoxide hydrolase, with defensive, anti-inflammatory and detoxifying functions (100). The mechanisms of the wound healing phases of *C. odorata* are briefly demonstrated in Fig. 3.

Inflammation is a response to tissue injury caused by infection, trauma, chemicals, heat, or unrecognized particles (129). During the acute response, inflammation causes an influx of neutrophils to the wound area. Free radicals are produced from these cells as part of the characteristic 'respiratory burst' activity (130). Free radicals are also generated by




Figure 2. Chemical structures of bioactive components of *Chromolaena odorata*. (A) Stigmasterol, (B) Scutellarein tetramethyl ether, (C) Quercetin, (D-1) Aromadendrin 4'-methyl ether: R₁ = OH; R₂, R₃ = H; R₄ = CH₃, (D-2) Eriodictyol 7,4'-dimethyl ether: R₁ = H; R₂, R₄ = CH₃; R₃ = OH, (D-3) Naringenin 4'-methyl ether: R₁, R₂, R₃ = H; R₄ = CH₃, (D-4)Taxifolin 4'-methyl ether: R₁, R₃ = OH; R₂ = H; R₄ = CH₃, (D-5)Taxifolin 7'-methyl ether: R₁, R₃ = OH; R₂ = CH₃; R₄ = H, (E) Sinensetin, (F) Caryophyllene oxide, (G-1) Quercetin 7,4'-dimethyl ether: R₁, R₃ = H; R₂, R₄ = CH₃, (G-2)Kaempferol 4'-methyl ether: R₁, R₂, R₃ = H; R₄ = CH₃, (G-3)Quercetin 3-*O*-rutinoside: R₁ = glu (6-1)rhams; R₂, R₄ = H; R₃ = OH, (G-4)Kaempferol 3-*O*-rutinoside: R₁ = glu (6-1)rhams; R₂, R₃, R₄ = H, (G-5)Quercetin 4'-methyl ether: R₁, R₂ = H; R₃ = OH; R₄ = CH₃, (G-6) Quercetin 7'-methyl ether: R₁, R₄ = H; R₂ = CH₃; R₃ = OH, (H) Isosakuranetin.

wound-associated non-phagocytic cells by mechanisms involving non-phagocytic NADPH oxidase (131). Therefore, the wound area has high levels of oxygen- and nitrogen-centered reactive species, and their derivative molecules. Oxidative stress is caused by these radicals and causes lipid peroxidation, DNA damage and enzyme inactivation, including free-radical scavenging proteins. Reports of the effects of oxidants in the pathogenesis of various diseases suggests that antioxidants may be useful as therapeutics in such conditions. In patients, topical application of free-radical-scavenging molecules has been reported to markedly improve wound healing and prevent from oxidative damage to tissues (132).

Inflammation upregulates several proinflammatory cytokines. Cyclooxygenase-2 and inducible nitric oxide synthase are important proinflammatory enzymes in inflammation (133,134). They produce proinflammatory mediators, prostaglandin E₂ and nitric oxide, which enhance the expression of proinflammatory cytokines including tumor necrosis factor- α and interleukin-1 β . *C. odorata* is capable of anti-inflammatory activity *in vitro* and *in vivo* (135-138). The Scu, isosakuranetin and stigmasterol have also been reported to possess anti-inflammatory activity (69,127,128,139-141).

Wound repair involves an immune-mediated physiological mechanism (4), and several plants and herbs have been traditionally and experimentally used to treat skin disorders, including wounds (142,143). Enhanced healing activity has been attributed to increased collagen

formation and angiogenesis (144,145). Collagen is a principal component of connective tissue, and provides a structural framework for the regenerating tissue (146). Furthermore, angiogenesis is required to improve circulation to the wound site, thus, providing oxygen and nutrients for the healing process (147-149). Histological analysis of healed wounds treated with *C. odorata* extract revealed increased fibroblast proliferation, collagen synthesis and neovascularization, resulting in an increased wound tensile strength and accelerated healing wound, compared with untreated wounds (100-102). The proliferative phase of wound healing follows, and usually overlaps with, the inflammatory phase, and is characterized by epithelial cell proliferation and migration over the provisional matrix within the wound (re-epithelialization) (4,21). It is well established that *C. odorata* enhances the proliferation of various cell types, including dermal fibroblasts, endothelial cells and epidermal keratinocytes, which may partially explain the beneficial clinical effects on the wound healing process (54,55,85,86,94,95,101,102).

Reactive oxygen species (ROS) disrupt wound healing due to their damaging effects on cells and tissues. ROS are able to degrade absorbable synthetic biomaterials (150,151). Free-radical-scavenging enzymes are cytoprotective and are essential for the reducing, deactivating and removing of ROS, and for wound healing regulation. Inflammatory disease pathology involves excessive ROS generation by polymorphonuclear leukocytes (PMNLs). Natural compounds with

Table II. Biological activity of different parts of *C. odorata*.

Serial no.	Part of plant	Biological activity	Refs.
1	Aqueous extract of aerial part and essential oil	Anti-malarial, anti-inflammatory, antibacterial	70,135
2	Ethanol, dichloromethane and methanol extract of whole plant	Analgesic, anti-inflammatory, antipyretic, antibacterial	73,82,101,102,110,111
3	Methanol, ethanol and aqueous extract of the leaf	Antioxidant, anti-inflammatory, wound healing properties, anti-staphylococcal, induces apoptosis and autophagy	54,55,66,85,87,109
4	Flower	Antibacterial, Mycobacterium tuberculosis, anticancer	87,92
5	Methanol extract of whole plant	Platelet activating factor receptor binding inhibitory activity	69




Figure 3. Schematic diagram showing the cellular and bio-physiologic events associated with the *Chromolaena odorata* wound healing mechanism of action and other pharmacological activities. *C. odorata* extract or its bioactive principles stimulate hemostatic activity by stimulation of TXS and repression of MMP-9 expressions. It also activates MEK, p38 MAPK, AKT and JNK kinase pathways which initiated the expression of HO-1. The induction of HO-1 will inhibit an inflammation and stimulate cell proliferation, thereby enhancing neovascularization and cell migration that helps to accomplish wound healing. *C. odorata* also increase antioxidant, antidiabetic activity, adhesion complex proteins expression and induce apoptosis and autophagy in tumor cells (modified from Pandith *et al*, 2013). TXS, thromboxane synthase; MMP, matrix metalloproteinase; MEK, MAPK kinase; MAPK, mitogen-activated protein kinase; AKT, protein kinase B; JNK, c-Jun N-terminal kinase; HO, heme oxygenase; ECM, extracellular matrix; NF-κB, nuclear factor κ-light-chain-enhancer of activated B cells; pIKK, phosphatidylinositol 3-kinase-related-kinase; Cox-2, cyclooxygenase-2; iNOS, inducible nitric oxide synthase; LC3, light chain 3; PAF, platelet activating factor.

antioxidant activity may be useful in reducing or regulating the oxidative damage caused by ROS produced from PMNLs. A previous study reported that *Chromolaena* species inhibit ROS generation via opsonized zymosan-stimulated PMNLs (83).

C. odorata may also contribute to wound healing by stimulating the production of antioxidants at the wound site, therefore protecting tissues from oxidative damage and providing a favorable environment for tissue healing (145). The antioxidant enzymes superoxide dismutase and catalase are known to quench the superoxide radical and prevent free radical-mediated damage to cells (152). Other active compounds within *C. odorata*, including triterpenes, alkaloids, flavonoids, and biomolecules (153) have been reported to have antioxidant activity and may, therefore, support wound healing (154). Thus, the enhanced wound healing stimulated by *C. odorata* may be due to the free radical scavenging action of the plant, as well as enhanced antioxidant enzyme levels. Similarly, *Tephrosia purpurea* has been reported to contain same flavonoids, which may be one of the potential mechanisms contributing to its enhancement of wound healing (153). In conclusion, flavonoids can scavenge ROS and free radicals, which are reactive intermediates that are potentially implicated in delaying wound healing (155-159).

6. Conclusion

Although *C. odorata* exhibits a wide spectrum of pharmacological activities, the field of wound healing is fraught with challenges, including understanding wounds themselves, and investigating the known and unknown constituents of natural products. For >30 years, researchers have investigated the healing efficacy of *C. odorata* in attempts to justify the inclusion of this plant in the management strategy of wound healing. This review has aimed to summarize these findings, in the hopes of enhancing the understanding of the benefits of *C. odorata* and contributing to assessments of its usefulness as claimed by the communities that use it for its wound healing properties. While the plant is commonly available, it is primarily known worldwide as a harmful weed. However, due to the increasing global interest in medicinal herbs, it has been predicted that medicinal herbs and plants are likely to be the focus of medicinal practice in the future. *C. odorata* and its constituents have proven to be helpful in enhancing wound healing activities, therefore, further research is expected to examine the purified constituents to enhance understanding of the mechanisms underlying its wound healing activity. This envisaged preclinical research may ultimately progress to translational clinical trials. *C. odorata* has been proven safe for application (84-85) and, therefore, its activity as a wound-healing agent for superficial and internal wounds, such as gastric ulcers, should be further investigated for its potential to provide affordable healthcare for wound management.

References

- Bennet RG: Fundamentals of cutaneous surgery. Mosby C.V., St. Louis, MO, p778, 1988.
- Singh M, Govindarajan R, Nath V, Rawat AK and Mehrotra S: Antimicrobial, wound healing and antioxidant activity of *Plagiochasma appendiculatum* Lehm. et Lind. Journal of Ethnopharmacology 107, 67-72, 2006.
- Nagori BP and Solanki R: Role of medicinal plants in wound healing. Res J Med Plant 5: 392-405: 2011.
- Singer AJ and Clark RA: Cutaneous wound healing. N Engl J Med 341: 738-746, 1999.
- Edlich RF, Winters KL, Britt LD, Long WB III, Gubler KD and Drake DB: Difficult wounds: An update. J Long Term Eff Med Implants 15: 289-302, 2005.
- Wietecha MS and DiPietro LA: Therapeutic approaches to the regulation of wound angiogenesis. Adv Wound Care (New Rochelle) 2: 81-86, 2013.
- Wound Management, Forecast to 2021: Established and emerging products, technologies and markets in the Americas, Europe, Asia/Pacific and Rest of World, <http://woundcare-today.com/news/world-at-glance/projected-global-wound-prevalence-by-wound-types>: March 2013.
- WHO report: <http://www.who.int/mediacentre/factsheets/fs365/en/>:2014.
- Hostetler SG, Xiang H, Gupta S, Sen C and Gordillo JM: Discharge patterns of injury-related hospitalizations with an acute wound in the United States. Wounds 18: 340-351, 2006.
- Belmont PJ, Schoenfeld AJ and Goodman G: Epidemiology of combat wounds in operation iraqi freedom and operation enduring freedom: Orthopaedic burden of disease. J Surg Orthop Adv 19: 2-7, 2010.
- Bodeker G and Hughes MA: Wound healing, traditional treatments and research policy. In Etkin N, Prendergast H and Houghton P (eds): Plants for Food and Medicine, 345-349, 1998.
- Bodeker GC, Ryan TJ and Ong CK: Traditional Approaches to Wound Healing. Clin Dermatol 17: 93-98, 1999.
- Burford G, Bodeker G and Ryan TJ: Skin and wound care: Traditional, complementary and alternative medicine in public health dermatology. In: Bodeker G, Burford G. Traditional, Complementary & Alternative Medicine: Policy and Public Health Perspectives, Imperial College Press, London, 2007.
- Trung LT and Bodeker G: Traditional medicine and the infrastructure for burn care in Vietnam. Trop Doct 27: 39-42, 1997.
- Porras-Reyes BH, Lewis WH, Roman J, Simchowitz L and Mustoe TA: Enhancement of wound healing by the alkaloid taspine defining mechanism of action. Proc Soc Exp Biol Med 203: 18-25, 1993.
- Suh DY and Hunt TK: Time line of wound healing. Clin Podiatr Med Surg 15: 1-9, 1998.
- Udupa SL, Shetty S, Udupa AL and Somayaji SN: Effect of *Ocimum sanctum* Linn. on normal and dexamethasone suppressed wound healing. Ind J Exp Biol 44: 49-54, 2006.
- Ghosh PK and Gaba A: Phyto-extracts in wound healing. J Pharm Pharm Sci 16: 760-820, 2013.
- Barreto RS, Albuquerque-Júnior RL, Araújo AA, Almeida JR, Santos MR, Barreto AS, DeSantana JM, Siqueira-Lima PS, Quintans JS and Quintans-Júnior LJ: A systematic review of the wound-healing effects of monoterpenes and iridoid derivatives. Molecules 19: 846-862, 2014.
- Soni H and Singhai AK: A recent update of botanicals for wound healing activity. Int Res J Pharm 3: 1-7, 2013.
- Fleischner AM: Plant extracts: To accelerate healing and inflammation. Cosmet Toilet 100: 45-58, 1985.
- Getie M, Mariam GT, Reitz R and Neubert RH: Evaluation of the release profiles of flavonoids from topical formulations of the crude extract of the leaves of *Dodonaea viscosa* (Sapindaceae). Pharmazie 57: 320-322, 2002.
- Tsuchiya H, Sato M, Miyazaki T, Fujiwara S, Tanigaki S, Ohyama M, Tanaka T and Inuma M: Comparative study on the antibacterial activity of phytochemical flavonoids against methicillin-resistant *Staphylococcus aureus*. J Ethnopharmacol 50: 27-34, 1996.
- Divakar MC, Devi LS, Kumar S and Rao SB: Studies on wound healing property of *Polyscias scutellaria* leaf saponins. Ind J Nat Prod 17: 37-42, 2001.
- Padmaja PN, Bairy KL and Kulkarni DR: Pro-healing effect of betel nut and its polyphenols. Fitoterapia 65, 298-300, 2000.
- Scortichini M and Rossi MP: Preliminary in vitro evaluation of the antimicrobial activity of terpenes and terpenoids towards *Erwinia amylovora* (Burrill). J Appl Bacteriol 71: 109-112, 1991.
- Biswas TK and Mukherjee B: Plants medicines of Indian origin for wound healing activity: A review. Int J Low Extrem Wounds 2: 25-39, 2003.
- Purna SK and Babu M: Collagen based dressing - A review. Burns 26: 54-62, 2006.
- Azaizeh H, Fulder S, Khalil K and Said O: Ethnobotanical knowledge of local Arab practitioners in the Middle Eastern Region. J Fitoterapia 74: 98-108, 2003.

30. Ragupathy S, Steven NG, Maruthakutti M, Velusamy B and Ul-Huda MM: Consensus of the 'Malasars' traditional aboriginal knowledge of medicinal plants in the Velliangiri holy hills, India. *J Ethnobiol Ethnomed* 4: 8, 2008.
31. Au DT, Wu J, Jiang Z, Chen H, Lu G and Zhao Z: Ethnobotanical study of medicinal plants used by Hakka in Guangdong, China. *J Ethnopharmacol* 117: 41-50, 2008.
32. Kumar B, Vijayakumar M, Govindarajan R and Pushpangadan P: Ethnopharmacological approaches to wound healing-exploring medicinal plants of India. *J Ethnopharmacol* 114: 103-113, 2007.
33. de Fátima A, Modolo LV, Sanches AC and Porto RR: Wound healing agents: The role of natural and non-natural products in drug development. *Mini Rev Med Chem* 8: 879-888, 2008.
34. Fleck CA and Simman R: Modern collagen wound dressings: Function and purpose. *J Am Col Certif Wound Spec* 2: 50-54, 2011.
35. Korkina L, Kostyuk V, De Luca C and Pastore S: Plant phenylpropanoids as emerging anti-inflammatory agents. *Mini Rev Med Chem* 11: 823-835, 2011.
36. Morgan C and Nigam Y: Naturally derived factors and their role in the promotion of angiogenesis for the healing of chronic wounds. *Angiogenesis* 16: 493-502, 2013.
37. Majumder P: Taxo-cognostic, Phyto-physicochemical & Biological screening of a plant: Taxo-cognostic, Phytochemical, Physicochemical parameters & Biological screening of *Zyziphus oenoplia* (L.) Mill plant root. LAP Lambert Academic Publishing, 2012.
38. Akinmoladun AC, Obuotor EM and Farombi EO: Evaluation of antioxidant and free radical scavenging capacities of some Nigerian indigenous medicinal plants. *J Med Food* 13: 444-451, 2010.
39. Kameshwaran S, Senthilkumar R, Thenmozhi S and Dhanalakshmi M: Wound healing potential of ethanolic extract of *tecoma stans* flowers in rats. *Pharmacologia* 5: 215-221, 2014.
40. Chaudhari M and Mengi S: Evaluation of phytoconstituents of *Terminalia arjuna* for wound healing activity in rats. *Phytother Res* 20: 799-805, 2006.
41. Moura-Letts G, Villegas LF, Marçalo A, Vaisberg AJ and Hammond GB: In vivo wound-healing activity of oleanolic acid derived from the acid hydrolysis of *Anredera diffusa*. *J Nat Prod* 69: 978-979, 2006.
42. Trombetta D, Puglia C, Perri D, Licata A, Pergolizzi S, Lauriano ER, De Pasquale A, Saija A and Bonina FP: Effect of polysaccharides from *Opuntia ficus-indica* (L.) cladodes on the healing of dermal wounds in the rat. *Phytomedicine* 13: 352-358, 2006.
43. Oztürk N, Korkmaz S, Oztürk Y and Başer KH: Effects of gentiopicridose, sweroside and swertiamarine, secoiridoids from *Gentiana lutea* sp. symphyandra, on cultured chicken embryonic fibroblasts. *Planta Med* 72: 289-294, 2006.
44. Ozgen U, Ikbal M, Hacımuftuoğlu A, Houghton PJ, Gocer F, Dogan H and Coskun M: Fibroblast growth stimulation by extracts and compounds of *Onosma argentatum* roots. *J Ethnopharmacol* 104: 100-103, 2006.
45. Maquart FX, Chastang F, Simeon A, Birembaut P, Gillery P and Wegrowski Y: Triterpenes from *Centella asiatica* stimulate extracellular matrix accumulation in rat experimental wounds. *Eur J Dermatol* 9: 289-296, 1999.
46. Shukla A, Rasik AM, Jain GK, Shankar R, Kulshrestha DK and Dhawan BN: In vitro and in vivo wound healing activity of asiaticoside isolated from *Centella asiatica*. *J Ethnopharmacol* 65: 1-11, 1999.
47. Hong SS, Kim JH, Li H and Shim CK: Advanced formulation and pharmacological activity of hydrogel of the titrated extract of *C. asiatica*. *Arch Pharmacol Res* 28: 502-508, 2005.
48. Fu SC, Hui CW, Li LC, Cheuk YC, Qin L, Gao J and Chan KM: Total flavones of *Hippophae rhamnoides* promotes early restoration of ultimate stress of healing patellar tendon in a rat model. *Med Eng Phys* 27: 313-321, 2005.
49. Jagetia GC and Rajanikant GK: Role of curcumin, a naturally occurring phenolic compound of turmeric in accelerating the repair of excision wound, in mice whole-body exposed to various doses of gamma-radiation. *J Surg Res* 120: 127-138, 2004.
50. Paiva LA, de Alencar Cunha KM, Santos FA, Gramosa NV, Silveira ER and Rao VS: Investigation on the wound healing activity of oleo-resin from *Copaifera langsdorffi* in rats. *Phytother Res* 16: 737-739, 2002.
51. Bråkenhielm E, Cao R and Cao Y: Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. *FASEB J* 15: 1798-1800, 2001.
52. Khanna S, Venojarvi M, Roy S, Sharma N, Trikha P, Bagchi D, Bagchi M and Sen CK: Dermal wound healing properties of redox-active grape seed proanthocyanidins. *Free Radic Biol Med* 33: 1089-1096, 2002.
53. Stevenson PC, Simmonds MS, Sampson J, Houghton PJ and Grice P: Wound healing activity of acylated iridoid glycosides from *Scrophularia nodosa*. *Phytother Res* 16: 33-35, 2002.
54. Phan TT, Wang L, See P, Grayer RJ, Chan SY and Lee ST: Phenolic compounds of *Chromolaena odorata* protect cultured skin cells from oxidative damage: Implication for cutaneous wound healing. *Biol Pharm Bull* 24: 1373-1379, 2001.
55. Phan TT, Hughes MA and Cherry GW: Effects of an aqueous extract from the leaves of *Chromolaena odorata* (Eupolin) on the proliferation of human keratinocytes and on their migration in an in vitro model of reepithelialization. *Wound Repair Regen* 9: 305-313, 2001.
56. Choi SW, Son BW, Son YS, Park YI, Lee S and Chung MH: The wound-healing effect of a glycoprotein fraction isolated from *Aloe vera*. *Br J Dermatol* 145: 535-545, 2001.
57. Villegas LF, Marçalo A, Martin J, Fernández ID, Maldonado H, Vaisberg AJ and Hammond GB: (+)-epi-Alpha-bisabolol [correction of bisbolol] is the wound-healing principle of *Peperomia galioides*: Investigation of the in vivo wound-healing activity of related terpenoids. *J Nat Prod* 64: 1357-1359, 2001.
58. Kusano A, Seyama Y, Nagai M, Shibano M and Kusano G: Effects of fukinolic acid and cimicifugic acids from *Cimicifuga* species on collagenolytic activity. *Biol Pharm Bull* 24: 1198-1201, 2001.
59. Burgalassi S, Raimondi L, Pirisino R, Banchelli G, Boldrini E and Saettoni MF: Effect of xyloglucan (tamarind seed polysaccharide) on conjunctival cell adhesion to laminin and corneal epithelium wound healing. *Euro J Ophthalmol* 10: 71-76, 2000.
60. Joshi A, Sengar N, Prasad SK, Goel RK, Singh A and Hemalatha S: Wound-healing potential of the root extract of *Albizia lebbek*. *Planta Med* 79: 737-743, 2013.
61. Singh MR, Saraf S, Vyas A, Jain V and Singh D: Innovative approaches in wound healing: Trajectory and advances. *Artificial Cells Nanomed Biotechnol* 41: 202-212, 2013.
62. Heywood VH, Harborne JB and Turner BL: *Biology and Chemistry of the Compositae*. Vol. 1. Academic Press, London: 1977.
63. Binggeli P: *Chromolaena odorata* (L.) King & Robinson (Asteraceae). <http://members.lycos.co.uk/WoodyPlantEcology>. *Woody Plant Ecology-Invasive Woody Plants*. Pierre Binggeli: 1999.
64. Bamikole MA, Ikhatua UJ and Osemwenkhae AE: Converting bush to meat: A case of *Chromolaena odorata* feeding to rabbits. *Pakistan Journal of Nutrition* 3: 258-261, 2004.
65. Igboh MN, Ikewuchi JC and Ikewuchi CC: Chemical profile of *Chromolaena odorata* L. (King and Robinson) leaves. *Pakistan Journal of Nutrition* 8: 521-524, 2009.
66. Akinmoladun AC, Ibukun EC and DanOloge IA: Phytochemical constituents and antioxidant properties of extracts from the leaves of *Chromolaena odorata*. *Sci Res Essays* 2: 191-194, 2007.
67. Akinmutimi AH and Akufo A: The effect of graded levels of dietary inclusion of siam weed (*Chromolaena odorata*) leaf meal in grower rabbits diet in a tropical environment. *J Ani Vet Adv* 5: 707-711, 2006.
68. King RM and Robinson H: Studies in the Eupatoriaceae (Compositae). The Genus *Chromolaena*. *Phytologia* 20: 196-209, 1970.
69. Ling SK, Pissar MM and Man S: Platelet-activating factor (PAF) receptor binding antagonist activity of the methanol extracts and isolated flavonoids from *Chromolaena odorata* (L.) King and Robinson. *Biol Pharm Bull* 30: 1150-1152, 2007.
70. Owoyele VB, Adediji JO and Soladoye AO: Anti-inflammatory activity of aqueous leaf extract of *Chromolaena odorata*. *Inflammopharmacol* 13: 479-484, 2005.
71. Akinmoladun AC, Obuotor EM and Farombi EO: Evaluation of antioxidant and free radical scavenging capacities of some Nigerian indigenous medicinal plants. *J Med Food* 13: 444-451, 2010.
72. Ambika SR and Jayachandra: Influence of light on seed germination in *Eupatorium odoratum* L. *Ind Forester* 106: 637-640, 1980.
73. Irobi ON: Activities of *Chromolaena odorata* (Compositae) leaf extract against *Pseudomonas aeruginosa* and *Streptococcus faecalis*. *J Ethnopharmacol* 37: 81-83, 1992.
74. Bennett FD and Rao VP: Distribution of an introduced weed *Eupatorium odoratum* L. in Asia and Africa and possibilities of its biological control. *PANS C* 14: 277-281, 1968.

75. Rai SN: Eupatorium and weedcides. Ind Forester 102: 449-454, 1976.
76. Warea O: *Chromolaena* (Siam) weed. Pest Advisory Leaflet no. 43, Secretariat of the Pacific Community, 2004.
77. Bani G: Status and management of *Chromolaena odorata* in congo. Proceedings of the fifth international workshop on biological control and management of *Chromolaena odorata*: 71-73, 2002.
78. Sajise PE, Palis RK, Norcio NV and Lales JS: The Biology *C. odorata* L. King and Robinson. Flowering behaviour, pattern of growth and nitrate metabolism. Phil Weed Sci Bull 1: 17-24, 1974.
79. Muniappan R and Bamba J: Biological control of *Chromolaena odorata*: Successes and Failures. Proceedings of the X International Symposium on Biological Control of Weeds 81, 1999, Montana State University, Bozeman, Montana, USA. Neal R. Spencer [ed.], 2000, 81-85.
80. Rejitha G: Diuretic activity of *Eupatorium odoratum* L inn. J Pharm Res 2: 844-846, 2009.
81. Vital PG and Windell LR: Antimicrobial activity and cytotoxicity of *Chromolaena odorata* (L. f.) King and Robinson and *Uncaria perrottetii* (A. Rich) Merr. Extracts. J Med Plants Res 3: 511-518, 2009.
82. Hanh TT, Hang DT, Van Minh C and Dat NT: Anti-inflammatory effects of fatty acids isolated from *Chromolaena odorata*. Asian Pac J Trop Med 4: 760-763, 2011.
83. Taleb-Contini SH, Kanashiro A, Kabeya LM, Polizello AC, Lucisano-Valim YM and Oliveira DC: Immunomodulatory effects of methoxylated flavonoids from two *Chromolaena* species: Structure-activity relationships. Phytother Res 20: 573-575, 2006.
84. Nasasombat S and Teckchuen N: Antimicrobial, antioxidant and anticancer activities of Thai local vegetables. J Med Plants Res 3: 443-449, 2009.
85. Thang PT, Patrick S, Teik LS and Yung CS: Anti-oxidant effects of the extracts from the leaves of *Chromolaena odorata* on human dermal fibroblasts and epidermal keratinocytes against hydrogen peroxide and hypoxanthine-xanthine oxidase induced damage. Burns 27: 319-327, 2001.
86. Torrenegra RD and Rodríguez OE: Chemical and biological activity of leaf extracts of *Chromolaena leivensis*. Nat Prod Commun 6: 947-950, 2011.
87. Harun FB, Syed Sahil Jamalullail SM, Yin KB, Othman Z, Tilwari A and Balaran P: Autophagic cell death is induced by acetone and ethyl acetate extracts from *Eupatorium odoratum* in vitro: Effects on MCF-7 and vero cell lines. Sci World J: 439-479, 2012.
88. Kouamé PB, Jacques C, Bedi G, Silvestre V, Loquet D, Barillé-Nion S, Robins RJ and Tea I: Phytochemicals isolated from leaves of *Chromolaena odorata*: Impact on viability and clonogenicity of cancer cell lines. Phytother Res 27: 835-840, 2013.
89. Subramoniam A, Asha VV, Nair SA, Sasidharan SP, Sureshkumar PK, Rajendran KN, Karunagaran D and Ramalingam K: Chlorophyll revisited: Anti-inflammatory activities of chlorophyll a and inhibition of expression of TNF- α gene by the same. Inflammation 35: 959-966, 2012.
90. Leonora PN and Elena SC: Anti-immunosuppressive Effects of *Chromolaena odorata* (Lf.) King & Robinson (Asteraceae) leaf extract in cyclophosphamide-injected Balb/C mice. philippine. J Sci 141: 35-43, 2012.
91. Vaisakh MN and Pandey A: The invasive weed with healing properties: A review on *Chromolaena odorata*. Int J Pharmaceutical Sci Res 3: 80-83, 2013.
92. Suksamrarn A, Chotipong A, Suavansri T, Boongird S, Timsuksai P, Vimuttipong S and Chuaynugul A: Antimycobacterial activity and cytotoxicity of flavonoids from the flowers of *Chromolaena odorata*. Arch Pharm Pres 27: 507-511, 2004.
93. Wang L, Waltenberger B, Pferschy-Wenzig EM, Blunder M, Liu X, Malainer C, Blazevic T, Schwaiger S, Rollinger JM, Heiss EH, et al: Natural product agonists of peroxisome proliferator-activated receptor gamma (PPAR γ): A review. Biochem Pharmacol 92: 73-89, 2014.
94. Phan TT, Hughes MA and Cherry GW: Enhanced proliferation of fibroblasts and endothelial cells treated with an extract of the leaves of *Chromolaena odorata* (Eupolin), an herbal remedy for treating wounds. Plast Reconstr Surg 101: 756-765, 1998.
95. Phan TT, Allen J, Hughes MA, Cherry G and Wojnarowska F: Upregulation of adhesion complex proteins and fibronectin by human keratinocytes treated with an aqueous extract from the leaves of *Chromolaena odorata* (Eupolin). Eur J Dermatol 10: 522, 2000.
96. Raina R, Parwez S, Verma PK and Pankaj NK: Medicinal plants and their role in wound healing. OnlineVet J 3: 21, 2008.
97. Ayyanar M and Ignacimuthu S: Ethnomedicinal plants used by the tribals of Tirunelveli hills to treat poisonous bites and skin diseases. Ind J Trad Knowled 4: 229-236, 2005.
98. Akinmoladun AC, Ibukun EO and Don-Ologe IA: Phytochemicals constituents and antioxidant properties of extracts from the leaves of *Chromolaena odorata*. Sci Res Essay 2: 191-194, 2007.
99. Zhang ML, Irwin D, Li XN, Sauriol F, Shi XW, Wang YF, Huo CH, Li LG, Gu YC and Shi QW: PPAR γ agonist from *Chromolaena odorata*. J Nat Prod 75: 2076-2081, 2012.
100. Heiss EH, Tran TV, Zimmermann K, Schwaiger S, Vouk C, Mayerhofer B, Malainer C, Atanasov AG, Stuppner H and Dirsch VM: Identification of chromomeric acid C-1 as an Nrf2 activator in *Chromolaena odorata*. J Nat Prod 77: 503-508, 2014.
101. Pandith H, Zhang X, Thongpraditchote S, Wongkrajang Y, Gritsanapan W and Baek SJ: Effect of Siam weed extract and its bioactive component scutellarein tetramethyl ether on anti-inflammatory activity through NF- κ B pathway. J Ethnopharmacol 147: 434-441, 2013.
102. Pandith H, Zhang X, Liggett J, Min KW, Gritsanapan W and Baek SJ: Hemostatic and wound healing properties of *chromolaena odorata* Leaf Extract. ISRN Dermatol 2013: 168269, 2013.
103. Okuno Y, Nakamura-Ishizu A, Kishi K, Suda T and Kubota Y: Bone marrow-derived cells serves as proangiogenic macrophages but no endothelial cells in wound healing. Blood 117: 5264-5272, 2011.
104. Martin A: The use of antioxidants in healing. Dermatol. Surg 22: 156-160, 1996.
105. Martin P: Wound healing-aiming for perfect skin regeneration. Science 276: 75-81, 1997.
106. Martin P and Leibovich SJ: Inflammatory cells during wound repair: The good, the bad and the ugly. Trends Cell Biol 15: 599-607, 2005.
107. Buffoni F, Banchelli G, Cambi S, Ignesti G, Pirisino R, Raimondi L and Vannelli G: Skin wound healing: Some biochemical parameters in guinea-pig. J Pharm Pharmacol 45: 784-790, 1993.
108. Pierce GF and Mustoe TA: Pharmacologic enhancement of wound healing. Annu Rev Med 46: 467-481, 1995.
109. Ling SK, Mazura MP, Khoo MGH, Virimala S, Ong BK, Mastura M, Nor Azah MA, Salbiah M, Siti Asha ABL and Rasadah MA: Chemical constituents and therapeutic potential of the leaf extracts from *Chromolaena odorata*. In: Highlights of FRIM's IRPA Projects 2005. Identifying Potential Commercial Collaborators Project Evaluation Meeting. Nik Zanariah NM, Norhara H, Nor Azman H and Chan HT (eds). Forest Research Institute Malaysia, Malaysia, pp108-114, 2005.
110. Odunbaku OA, Ilusanya OA and Akasoro KS: Antibacterial activity of ethanolic leaf extract of *Ficus exasperata* on *Escherichia coli* and *Staphylococcus albus*. Sci Res Essay 3: 562-564, 2008.
111. Owoyele BV, Oguntoye SO, Dare K, Ogunbiyi BA, Aruboula EA and Soladoye AO: Analgesic, anti-inflammatory and antipyretic activities from flavonoid fractions of *Chromolaena odorata*. J Med Plants Res 2: 219-225, 2008.
112. Bamba D, Bessière JM, Marion C, Pélissier Y and Fourasté I: Essential Oil of *Eupatorium odoratum*. Planta Med 59: 184-185, 1993.
113. Ayyanar M and Ignacimuthu S: Herbal medicines for wound healing among tribal people in Southern India: Ethnobotanical and Scientific evidences. Int J Appl Res Nat Prod 2: 29-42, 2009.
114. Reddy JS, Rao PR and Reddy MS: Wound healing effects of *Heliotropium indicum*, *Plumbago zeylanicum* and *Acalypha indica* in rats. J Ethnopharmacol 79: 249-251, 2002.
115. Gosain A and DiPietro LA: Aging and wound healing. World J Surg 28: 321-326, 2004.
116. Nguyen DT, Orgrill DP and Murphy GF: The pathophysiologic basis for wound healing and cutaneous regeneration. In: Biomaterials for Treating Skin Loss. Orgill D and Blanco G (eds). Woodhead Publishing, Cambridge, pp22-57, 2009.
117. Vezza R, Mezzasoma AM, Venditti G and Gresele P: Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets. Thromb Haemost 87: 114-121, 2002.
118. Aso Y: Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front Biosci 12: 2957-2966, 2007.
119. Phan TT, Hughes MA, Cherry GW, Le TT and Pham HM: An aqueous extract of the leaves of *Chromolaena odorata* (formerly *Eupatorium odoratum*) (Eupolin) inhibits hydrated collagen lattice contraction by normal human dermal fibroblasts. J Altern Complement Med 2: 335-343, 1996.

120. Fialkow L, Wang Y and Downey GP: Reactive oxygen and nitrogen species as signaling molecules regulating neutrophil function. *Free Radical Biol Med* 42: 153-164, 2007.
121. Wagener FA, van Beurden HE, von den Hoff JW, Adema GJ and Figdor CG: The heme-heme oxygenase system: A molecular switch in wound healing. *Blood* 102: 521-528, 2003.
122. Stamenkovic I: Extracellular matrix remodelling: The role of matrix metalloproteinases. *J Pathol* 200: 448-464.
123. Hirose Y, Chiba K, Karasugi T, Nakajima M, Kawaguchi Y, Mikami Y, Furuichi T, Mio F, Miyake A, Miyamoto T, *et al*: A functional polymorphism in THBS2 that affects alternative splicing and MMP binding is associated with lumbar-disc herniation. *Am J Human Genetic* 82: 1122-1129, 2002.
124. Akah PA: Mechanism of hemostatic activity of *Eupatorium odoratum*. *Int J Crude DrugRes* 28: 253-256, 1990.
125. Wongkrajang Y, Muagklum S, Peungvicha P, Jaiaraj P and Opartkiattikul N: *Eupatorium odoratum* linn: An enhancer of hemostasis. *Mahidol Univ J Pharmaceut Sci* 17: 9-13, 1990.
126. Wongkrajang Y, Thongpraditchote S, Nakornchai S, Chuakul W, Muangklum K and Jaiaraj P: Hemostatic activities of *Eupatorium odoratum* Linn.: Calcium removal extract. *Mahidol Univ J Pharmaceut Sci* 21: 143-148, 1994.
127. Triratana T, Suwannuraks R and Naengchomnong W: Effect of *Eupatorium odoratum* on blood coagulation. *J Med Assoc Thailand* 74: 283-287, 1991.
128. Gabay O, Sanchez C, Salvat C, Chevy F, Breton M, Nourissat G, Wolf C, Jacques C and Berenbaum F: Stigmasterol: A phytosterol with potential anti-osteoarthritic properties. *Osteoarthritis Cartilage* 18: 106-116, 2010.
129. Parimala DB, Tamilchelvan N and Ramasubramaniraja R: Inflammation and medicinal plants-an ethnomedical approach. *J Phytol* 2: 49-56, 2010.
130. Baboier BM: Oxygen-dependent microbial killing by phagocytes (first of two parts). *New Eng J Med* 29: 629-668, 1978.
131. Griendling KK: NAD(P)H oxidase: Role in cardiovascular biology and diseases. *Circ Res* 86: 494-501, 2000.
132. Thiem B and Gošlińska O: Antimicrobial activity of *Rubus chamaemorus* leaves. *Fitoterapia* 75: 93-95, 2003.
133. Kim JH, Kim DH, Baek SH, Lee HJ, Kim MR, Kwon HJ and Lee CH: Rengyolone inhibits inducible nitric oxide synthase expression and nitric oxide production by down-regulation of NF-kappaB and p38 MAP kinase activity in LPS stimulated RAW 264.7 cells. *Biochem Pharmacol* 71: 1198-1205, 2006.
134. Pan CH, Kim ES, Jung SH, Nho CW and Lee JK: Tectorigenin inhibits IFN-gamma/LPS-induced inflammatory responses in murine macrophage RAW 264.7 cells. *Arch Pharma Res* 31: 1447-1456, 2008.
135. Pisutthanan N, Liawruangrath S, Bremner J and Liawruangrath B: Chemical constituents and biological activities of *Chromolaena odorata*. *J Sci Fac Chiang Mai Univ* 32: 139-148, 2005.
136. Lessio C, de Assunção Silva F, Glória MA, Di Tommaso AB, Gori Mouro M, Di Marco GS, Schor N and Higa EM: Cyclosporine A and NAC on the inducible nitric oxide synthase expression and nitric oxide synthesis in rat renal artery cultured cells. *Kidney Int* 68: 2508-2516, 2005.
137. Park JW, Kwon OK, Jang HY, Jeong H, Oh SR, Lee HK, Han SB and Ahn KS: A leaf methanolic extract of *Wercklea insignis* attenuates the lipopolysaccharide-induced inflammatory response by blocking the NF-κB signaling pathway in RAW 264.7 macrophages. *Inflammation* 35: 321-331, 2012.
138. Sun J, Zhang X, Broderick M and Fein H: Measurement of nitric oxide production in biological systems by using griess reaction assay. *Sensors* 3: 276-284, 2003.
139. Lee IS, Jin W, Zhang X, Hung TM, Song KS, Seong YH and Bae K: Cytotoxic and COX-2 inhibitory constituents from the aerial parts of *Aralia cordata*. *Arch Pharmacol Res* 29: 548-555, 2006.
140. Dat NT, Lee K, Hong YS, Kim YH, Minh CV and Lee JJ: A peroxisome proliferator-activated receptor-gamma agonist and other constituents from *Chromolaena odorata*. *Planta Med* 75: 803-807, 2009.
141. Karodi R, Jadhav M, Rub R and Bafna A: Evaluation of the wound healing activity of a crude extract of *Rubia cordifolia* L. (Indian madder) in mice. *Int J Appl Res Nat Prod* 2: 12-18, 2009.
142. Csupor D, Blazsó G, Balogh A and Hohmann J: The traditional Hungarian medicinal plant *Centaurea sadleriana* Janka accelerates wound healing in rats. *J Ethnopharmacol* 127: 193-195, 2010.
143. Trabucchi E, Preis Baruffaldi F, Baratti C and Montorsi W: Topical treatment of experimental skin lesions in rats: Macroscopic, microscopic and scanning electron-microscopic evaluation of the healing process. *Int J Tissue React* 8: 533-544, 1986.
144. Shukla A, Rasik AM and Dhawan BN: Asiaticoside-induced elevation of antioxidant levels in healing wounds. *Phytother Res* 13: 50-54, 1999.
145. Cohen IK, Diegelmann RF and Lindblad WJ: Wound healing. *Biochem Clin Asp Philadelphia*: Saunders, 1992.
146. Szabo S, Kusstatscher S, Sakoulas G, Sandor Z, Vincze A and Jadus M: Growth factors: New 'endogeneous drug' for ulcer healing. *Scand J Gastroenterol Suppl* 210: 15-18, 1995.
147. Buntrock P, Jentzsch KD and Heder G: Stimulation of wound healing, using brain extract with fibroblast growth factor (FGF) activity. II. Histological and morphometric examination of cells and capillaries. *Exp Pathol* 21: 62-67, 1982.
148. Habibipour S, Oswald TM, Zhang F, Joshi P, Zhou XC, Dorsett-Martin W and Lineaweaver WC: Effect of sodium diphenylhydantion on skin wound healing in rats. *Plast Reconstr Surg* 112: 1620-1627, 2003.
149. Aliyev E, Sakallioğlu U, Eren Z and Açıköz G: The effect of polylactide membranes on the levels of reactive oxygen species in periodontal flaps during wound healing. *Biomaterials* 25: 4633-4637, 2004.
150. Umachigi SP, Kumar GS, Jayaveera K, Kishore KD, Ashok KC and Dhanapal R: Antimicrobial, wound healing and antioxidant activities of *Anthocephalus cadamba*. *Afr J Tradit Complement Altern Med* 4: 481-487, 2007.
151. Shirwaikar A, Malini S and Kumari SC: Protective effect of *Pongamia pinnata* flowers against cisplatin and gentamicin-induced nephrotoxicity in rats. *Ind J Exp Biol* 41: 58-62, 2003.
152. Sumitra M, Manikandan P and Suguna L: Efficacy of *Butea monosperma* on dermal wound healing in rats. *J Biochem Cell Biol* 37: 566-573, 2005.
153. Saleem M and Aftab A: Tephrosia purpurea ameliorates benzoyl peroxide induced cutaneous toxicity in mice: Diminution of oxidative stress. *Pharma Pharmacol Commun* 5: 455-461, 1999.
154. Lewis DA and Hanson PJ: Antiulcer drugs of plant origin. *Prog Med Chem* 8: 210-229, 1991.
155. Srinivasa Rao K, Chaudhury PK and Pradhan A: Evaluation of anti-oxidant activities and total phenolic content of *Chromolaena odorata*. *Food Chem Toxicol* 48: 729-732, 2010.
156. Onkaramurthy M, Veerapur VP, Thippeswamy BS, Reddy TN, Rayappa H and Badami S: Anti-diabetic and anti-cataract effects of *Chromolaena odorata* Linn., in streptozotocin-induced diabetic rats. *J Ethnopharmacol* 145: 363-372, 2013.
157. Ukwueze SE, Duru O and Shorinwa O: Evaluation of the cutaneous wound healing activity of solvent fractions of *Chromolaena odorata* linn. *IAJPR* 3: 3316-3323, 2013.
158. Boudjeko T, Megnekou R, Woguia AL, Kegne FM, Ngomoyogoli JE, Tchapoum CD and Koum O: Antioxidant and immunomodulatory properties of polysaccharides from *Allanblackia floribunda* Oliv stem bark and *Chromolaena odorata* (L.) King and H.E. Robins leaves. *BMC Res Notes* 8: 759, 2015.
159. Pitakpawasutthi Y, Thitikornpong W, Palanuvej C and Ruangrunsi N: Chlorogenic acid content, essential oil compositions, and in vitro antioxidant activities of *Chromolaena odorata* leaves. *J Adv Pharm Technol Res* 7: 37-42, 2016.